

## Supplement

### Supplemental Table 1. Discontinuation Rates

Time Point (Years)	Oral treatments*	Injectables†
0.5	27.4%	13.7%
1	29.3%	14.7%
1.5	23.7%	11.8%
2	23.0%	11.5%
2.5	30.8%	15.4%
3	25.9%	12.9%

\*Includes alendronate, risedronate, and ibandronate

†Includes denosumab, teriparatide, and zoledronate

### Supplemental Table 2. Relative Risk of Mortality Compared to Normal Male Population

Age	1 <sup>st</sup> year after hip fracture	1st year after clinical vertebral fracture	2+ years after hip fracture	2+ years after clinical vertebral fracture	NHNV
<b>75-79</b>	5.14	5.46	4.54	3.75	5.07
<b>80-84</b>	3.91	3.73	3.45	2.56	4.06
<b>85-89</b>	2.32	2.36	2.05	1.63	2.51
<b>90-94</b>	1.49	1.62	1.21	1.12	1.62

Note: Not adjusted for comorbidities

Source: Johnell et al. 2004 [36]